Transhiatal/Transabdominal Approach Compare With Thoracoabdominal Approach for Siewert II Adenocarcinoma of Esophagogastric Junction

Launched by CHINESE PLA GENERAL HOSPITAL · May 29, 2021

Keywords

ClinConnect Summary

This clinical trial is looking at two different surgical approaches to treat a specific type of cancer called Siewert II adenocarcinoma, which occurs at the junction where the esophagus meets the stomach. The researchers want to see whether a transhiatal/transabdominal approach or a thoracoabdominal approach is more effective for patients undergoing surgery for this type of cancer. They are currently recruiting participants aged 18 to 75 who have a confirmed diagnosis of this cancer and whose tumors are located at the esophagogastric junction.

To be eligible for the trial, participants should have good overall health (with some limitations) and be able to provide informed consent. Patients with cancer that has spread to other parts of the body or those with a history of certain surgeries or other malignancies within the last five years are not eligible. If you join the trial, you can expect close monitoring and support throughout the process as the researchers gather information to help improve treatment options for this type of cancer in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1.18\~75 years old
• • 2.The tumor center located at the esophagogastric junction(EGJ) line from 1cm above to 2cm below(SiewertⅡ) .
• • 3.Histological diagnosis of adenocarcinoma
• • 4. American Society of Anesthesiologists(ASA) physical status class is less than or equal to 3
• • 5.Informed consent of patients
• Exclusion Criteria:
• • 1.Patients with distant metastasis (M1) or invasion of surrounding organs
• • 2.History of esophagectomy and gastrectomy (including endoscopic mucosal resection/endoscopic submucosal dissection for gastric cancer and esophageal cancer)
• • 3.History of other malignant tumors within 5 years
• • 4.The researcher believes that the patient is not suitable to participate in the clinical trial
• • 5.Patients who persist in withdrawing from clinical trials